Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to b… Read more
Humacyte Inc (HUMA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 5.031x
Based on the latest financial reports, Humacyte Inc (HUMA) has a cash flow conversion efficiency ratio of 5.031x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.90 Million) by net assets ($-4.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Humacyte Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Humacyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Humacyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Humacyte Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
InnovAge Holding Corp
NASDAQ:INNV
|
0.089x |
|
Seche Environnem.
PA:SCHP
|
0.184x |
|
Vicore Pharma Holding AB (publ)
ST:VICO
|
-0.074x |
|
Hampidjan hf
IC:HAMP
|
0.016x |
|
Global Indemnity Group, LLC Class A Common Stock
NASDAQ:GBLI
|
0.000x |
|
Linhai Co Ltd
SHG:600099
|
0.103x |
|
Dutch Lady Milk Industries Bhd
KLSE:3026
|
0.119x |
|
CapMan Oyj Series B
LSE:0E1L
|
0.000x |
Annual Cash Flow Conversion Efficiency for Humacyte Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Humacyte Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-52.67 Million | $-98.12 Million | 1.863x | +134.43% |
| 2023-12-31 | $13.55 Million | $-73.31 Million | -5.412x | -789.60% |
| 2022-12-31 | $116.93 Million | $-71.13 Million | -0.608x | +8.46% |
| 2021-12-31 | $122.17 Million | $-81.19 Million | -0.665x | +15.48% |
| 2020-12-31 | $70.67 Million | $-55.57 Million | -0.786x | -44.80% |
| 2019-12-31 | $132.20 Million | $-71.79 Million | -0.543x | -- |